Genetically Altered Bacteria May Deliver Cancer Vaccines
Researchers are testing a new oral vaccine platform using genetically engineered Bifidobacterium to enhance anti-tumor immunity. This approach aims to complement existing immune checkpoint inhibitors by delivering cancer antigens more effectively than traditional injectable methods.
A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity. In an exploratory phase I clinical study, the vaccine was well tolerated and generated immunologic and clinical findings that warrant further investigation. The results also point to potential biomarkers that may help identify patients most likely to benefit from this approach.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in